Nurix Therapeutics, Inc.NRIXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank41
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P41
Within normal range
vs 3Y Ago
-1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-18.21%
Q3 20259.14%
Q2 2025-3.40%
Q1 2025-25.30%
Q4 2024-15.59%
Q3 2024-6.23%
Q2 20245.35%
Q1 2024-257.18%
Q4 2023164.88%
Q3 2023-122.71%
Q2 202361.88%
Q1 2023-27.66%
Q4 202218.04%
Q3 2022-40.69%
Q2 202222.79%
Q1 2022-37.91%
Q4 2021-3.13%
Q3 20214.96%
Q2 2021-491.59%
Q1 2021139.32%
Q4 2020-233.53%
Q3 202057.44%
Q2 2020-135.22%
Q1 2020421.40%
Q4 2019-135.05%
Q3 2019372.63%
Q2 2019-37.79%
Q1 20190.00%